Background: CASR gene appears to be involved in cancer biology and physiology. However, a number of studies investigating CASR polymorphisms and cancer risks have presented inconclusive results. Thus, a systematic review and a meta-analysis of the effect of CASR polymorphisms on several cancer risks were performed to suggest a statistical evidence for the association of CASR polymorphisms with cancer risks. 
Introduction
The effect of calcium intake on various cancer risks is an ongoing topic of investigation. Besides the physiologic calcium level, the calcium-sensing receptor (CaSR), through which calcium balance is regulated, is thought to play an important role in the regulation of cancer expression. The activated CaSR can stimulate intracellular signal pathways including mitogen-activated protein kinase, phosphatidylinositol 3 kinase/ protein kinase B, and cy-mic and cyclin D1 pathways; these processes are involved in cellular secretion, proliferation, differentiation, chemotaxis, and apoptosis. 1 The CaSR expression is related to the CASR gene that seems to have a role in cancer cells, acting both as a tumor suppressor and an oncogene, depending on the cancer site and environmental condition. In colonic epithelial cells, high calcium intake could reduce the risk of colorectal cancer development.
2 E-cadherin stimulated by CaSR can interact with β-catenin, an important protooncogene, contribute to reducing the cancer cell activity, and downregulate cell proliferation. 3 Whereas, the increased expression of CaSR by high calcium levels promoted MCF-7, PC-3, and C4-2B breast and prostate cancer cells known to metastasize to the bone and the cancer cell proliferation process is linked to extracellular signal-regulated kinases 1 and 2 (ERK 1/2) phosphorylation.
Recently, many studies have focused on the association between CASR gene polymorphism and multiple cancer risks. Three common nonsynonymous SNPs (rs1801725, rs1042636, and rs1801726) have been the primary research targets for cancer risk, but inconsistent results have been reported. Dong et al 13 reported that CASR variants are not associated with colorectal cancer risk, whereas Jenab et al 14 suggested possible association between CASR rs1042636 variations with colorectal cancer risk. Additional genetic variants of the large CASR gene (102 kb), which cannot be sufficiently explained by the three nonsynonymous SNPs, are also the research targets of cancer risks. Thus, a systematic review on the effect of CASR polymorphisms with several cancer risks and a meta-analysis on colorectal cancer risk were performed to suggest statistical evidence for the clinical use of cancer markers.
Methods

Search strategy and eligibility criteria
The electronic databases of MEDLINE, EMBASE, Web of Science, Scopus, and the HuGE Published Literature database were searched with the following keywords: ("calcium sensing receptor" OR "casr protein" OR "CASR" OR "Calcium sensing receptor gene") AND ("cancers" OR "neoplasia"). The references of included articles were checked to include any additional relevant articles.
A systematic search for relevant literature was performed to include studies published up to July 26, 2014, by two independent reviewers (JS and KJ) without language restrictions. Any disagreement was resolved by discussion between the authors. Inclusion criteria for article selection were as follows: 1) case-control studies or cohort studies and 2) sufficient data reporting odds ratio (OR) with 95% confidence interval (CI) or sample frequency with which the appropriate calculations could be done. Studies were excluded if they were 1) duplicate or previously published, 2) letters, reviews, or editorials, and 3) CASR gene studies on cell lines or animals by PRISMA flow diagram.
Data extraction
The following information was extracted from included studies: first author, year of publication, country of study site, ethnic group, genotyping method, number of genotyped cases and controls, genotype frequencies for cases and controls, selection pool of control population (population-based controls and hospital-based controls) and Hardy-Weinberg equilibrium (HWE) in any population, tumor type and site, OR, and corresponding 95% CI. Ethnicity was classified as Caucasian, Asian, or African. When the study did not specify the ethnicity, the term "mixed ethnicity" was used. Any discrepancies in the extracted information were resolved by discussion among the authors.
Quality score assessment
Two reviewers (JS and KJ) independently evaluated the quality of the selected studies using the quality assessment scoring tool developed for genetic association studies by Thakkinstian et al, 15 which was modified from previous metaanalyses of observational studies [16] [17] [18] [19] considering traditional epidemiologic and genetic issues 20, 21 (Table S1 ).
Statistical analysis
The association of three nonsynonymous CASR SNPs with colorectal cancer risk was examined by unconditional logistic regression to obtain ORs with 95% CIs in additive, dominant, and recessive genetic models and represented by forest plot. The pooled ORs were calculated for each genetic model and different cancer sites (eg, proximal colon, distal colon). Whenever ORs and 95% CIs were not reported, appropriate data were selected and calculated to produce OR with 95% CI. Between-study heterogeneity was assessed by the Q-statistic (heterogeneity was considered statistically significant if P,0.1) 22 and quantified by the I 2 value. Both fixed-and random-effects models were used to combine the aggregate data determined by the I 2 value. When I 2 was .50%, the random-effects model was used for analysis. Potential publication bias was assessed with the linear regression method of Egger's test 23 and funnel plot. 24 Statistical analyses were performed 
Results
Study selection
Twenty out of 1,309 publications were found to be eligible for systematic review as shown in Figure S1 . Among eligible publications, the study by Speer et al 25 was excluded due to an overlapping population with another study by the same author. 26 Also, a study for esophageal cancer 27 was excluded due to insufficient SNP information. By hand search, a study by Mahmoudi et al 28 was added, and the final number of studies included for systematic review was 19 (Table 1) .
In meta-analysis, two articles that reported colorectal cancer risk of rs1801725 were excluded because the reported frequency of homozygote variants was 0. Meta-analyses for colorectal cancer risk included 4,209 cases and 4,801 controls for rs1801725 and 5,557 cases and 5,552 controls for rs1042636 and rs1801726, respectively.
Synthesis of result by meta-analysis on the colorectal cancer risk
The association between rs1801725, rs1042636, rs1801726 and colorectal cancer risk, stratified by genetic model and cancer site, is presented in Table 2 . Figures 1-3 Figure 3 ).
Systematic reviews of the association of CASR polymorphisms with cancer risks
From 19 studies that reported CASR polymorphisms and cancer risks, we extracted significant SNPs associated with several cancer risks that could not be assessed by metaanalysis for future research targets stratified by cancer type and cancer site (Table 3) .
CASR SNPs
Having a T allele of rs1801725 is associated with clinical stage 4 (P=0.002) and the histological subgroup of undifferentiated neuroblastomas (P=0.046). 29 Patients with this polymorphism had significantly lower overall survival rates (P=0.022) and event-free survival rates (P=0.01) than those who had GG homozygotes.
African-American prostate cancer patients having advanced disease were approximately six times less carrying the homozygote minor allele of rs1801726 than were controls (P=0.01). 30 The polymorphism of rs17251221 demonstrated a noticeable association with prostate and breast cancer risk; carrying a homozygote variant increases the risk of breast and prostate cancer considerably. 31, 32 Haplotype and diplotypes
Colorectal adenoma risk was associated with diplotype (GAC/GAG) of rs1801725, rs1042636, and rs1801726 (OR =0.56 [95% CI: 0.36-0.88]). 33 The polymorphism of rs1801726 on this diplotype reduced distal colon adenoma risk by half compared with the diplotype only composed of wild types (GAC/GAC). The haplotype (CC) of rs4678174 and rs2270916 was associated with cancer risk compared with the wild-type haplotype (TT) in the proximal colon (OR =0.80 [95% CI: 0.67-0.97]). 13 29 
Diet effects and CASR polymorphisms
The polymorphisms of rs2270916, rs10934578, rs12485716, and rs4678174 were not associated with colorectal cancer risk; 34 however, with low calcium intake, the genetic association was significant. This correlation was also valid in a study for prostate cancer; 35 several SNPs were significant only under low calcium levels or low plasma vitamin D levels.
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Genetic polymorphisms of CASR and cancer risk Quality score assessment
The quality score of each study was graded: 13 studies were graded 8 and over and six studies were under 8 (Table S2) , and overall included studies are well designed: 13 studies have over 500 research subjects and 12 studies have population-based recruiting methods.
Publication bias
As a widely accepted tool for publication bias, Egger's linear regression methods and funnel plot were used. Overall, Egger's linear regression methods and funnel plots in rs1801725, rs1042636, and rs1801726 polymorphisms did not detect publication bias (Table 2 , Figures 1-3 ).
Discussion
In this review, we presented the novel findings of significant association between CASR rs1042636, rs1801726, and rs17251221 polymorphisms; rs1042636 decreased the colorectal cancer risk in proximal and distal sites, but rs1801726 increased the risk in distal colon site. The rs17251221 considerably increased the cancer risk in prostate and breast. The CASR encodes a polypeptide of 1,078 amino acids with seven membrane spanning helixes characteristic of G protein-coupled receptors (GPCRs). 36, 37 GPCRs have been known to have a direct link with cellular transformation with the discovery of MAS oncogene. 38 Wild-type GPCRs could become oncogenic by the excessive exposure to local or circulating agonists.
39-41
The G protein-coupled CaSR, through which calcium mediates its carcinogenesis, has been implicated in parathyroid gland cancer. 42 CaSR is also distributed through the entire gastrointestinal tract [43] [44] [45] [46] and reacts to the calcium concentrations in the lumen of the colon as well as circulating concentrations. 47, 48 Evidence from several studies [49] [50] [51] suggests that risk factors differ by site within the colorectum, and molecular and functional 
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Jeong et al differences result in different susceptibility to exposures and environment, such as diet. Thus, colorectal cancer risk was analyzed by proximal and distal colon sites in our research. The CASR gene carries three common nonsynonymous SNPs, each expressed at a much different allele frequency in three ethnic populations: rs1801725 (A986S) in Europeans (minor allele frequency: 13.3%), rs1042636 (R990G) in Asians (minor allele frequency: 50.4%), and rs1801726 (Q1011E) in Africans (minor allele frequency: 23.3%). 52 The most frequent SNP in the Caucasian ethnicity, rs1801725, did not show any association with colorectal cancer risk. This finding is consistent with studies included in this systematic review on pancreatic 53 and prostate cancers 35, 54 in Caucasians. The functional significance of this variant is small 
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Genetic polymorphisms of CASR and cancer risk by amino acid substitution, 55, 56 such that the outcome of cancer risk could be negligible. 13 The study of Masvidal et al 29 is the only one to demonstrate that having a T allele of rs1801725 is associated with later stage with significantly low overall and event-free survival in patients with neuroblastoma.
The rs1042636 (R990G) variant, which is frequently found in the Asian population, seems functionally relevant, as evidenced by cross-species evolutionary conservation. 57 Based on physical properties, the change from positively charged arginine (R) to hydrophilic glycine (G) at codon 990 results in different functionality. 58 This property is consistent with the results of this meta-analysis that GG genotype showed a decreased cancer risk by 25% compared to the wild-type AA genotype in the distal colon and by 32% in the proximal colon.
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Jeong et al Table 3 Significant SNPs or haplo/diplotype of CASR found in selected studies stratified by cancer sites Abbreviations: SNP, single-nucleotide polymorphism; OR, odds ratio; CI, confidence interval; NA, not applicable; HR, hazard ratio; P ACT , P-value adjusted for correlated tests.
According to a report by the Center for Disease Control in 2011, Africans had the highest rate of colorectal cancer, followed by Caucasian, Hispanic, Asian/Pacific Islander, and American Indian/Alaska Native. 59, 60 The results of our study that represent decreasing cancer risk by variant rs1042636 (high frequency in Asian) and increasing cancer risk by variant rs1801726 (high frequency in African) might explain part of the colorectal cancer risk by genetic causality.
One of the major risk factors of colorectal cancer is diet. 61 Specifically, calcium and dairy product intake have been studied, and high calcium intake is associated with decreased colorectal cancer risk. [62] [63] [64] [65] [66] [67] According to the study by Kim et al 34 on colorectal cancer and Shui et al 35 on prostate cancer, several SNPs are significant only under low calcium intake or low plasma vitamin D level and that SNPs of CASR are under strong influence of epigenetic factors and regulation of calcium and vitamin D intake is a vital factor in tumorigenesis. In fact, methylation of CASR was shown in 69% of colorectal cancer tissues and 90% of lymph node metastatic tissues and was strongly associated with reduced CaSR expression. 68 Both prostate and breast cancers of high mortality are strongly related to bone metastasis. 69 Approximately 75% of patients who develop advanced breast cancer will have secondary tumors in the bone, while in the case of prostate cancer, ~90% of patients who die of advanced prostate cancer develop bone metastases. 70, 71 Overexpression of CaSR can serve as a major target of calcium in facilitating the formation and growth of skeletal metastasis of prostate and breast cancers.
One of the important aspects of CaSR research is that CaSR is highly correlated with the response of chemotherapeutics. CaSR signaling regulates the expression of thymidylate synthase and survivin and facilitates 5-fluorouracil treatment, which is one of the drugs of choice in colon cancer chemotherapy. 72, 73 The treatment of paclitaxel, a mitotic inhibitor used in chemotherapy is also related with CaSR. Knocking down the tumor suppressor gene BRAC1 leads to a downregulation of CaSR expression and results in upregulation of survivin which reduced the cancer cell's sensitivity. 74 Therefore, CASR gene polymorphisms can be the research target for the cancer causality and improvement of chemotherapeutics.
The limitations of this study should be acknowledged. First, most of the studies were mainly on colorectal cancers in Caucasians, ethnic factors could not be evaluated in the meta-analysis. Second, the total number of cases and controls is ~10,000, which is not enough for a meta-analysis of genetic association study under Venice guidelines 75 to elucidate robust evidence. Third, several studies were performed under submit your manuscript | www.dovepress.com
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Conclusion
In summary, CASR polymorphisms are highly associated with cancer risks in various sites. The evaluation of CASR in clinical aspect as a cancer biomarker and in therapeutics should consider the ethnicity, environment and diet effects concomitantly. Further research stratified by cancer site, environmental impact, and ethnicity should be undertaken.
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